$18.7
Insights on Avanos Medical, Inc.
Revenue is up for the last 3 quarters, 169.4M → 173.3M (in $), with an average increase of 1.1% per quarter
Netprofit is up for the last 3 quarters, -68.1M → 10.5M (in $), with an average increase of 937.9% per quarter
In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 69.2%
In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 124.5%
0.59%
Downside
Day's Volatility :1.33%
Upside
0.74%
7.81%
Downside
52 Weeks Volatility :44.94%
Upside
40.27%
Period | Avanos Medical, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -2.35% | -0.7% | 0.0% |
6 Months | 0.32% | 6.6% | 0.0% |
1 Year | -37.47% | 3.7% | -1.5% |
3 Years | -58.08% | 14.0% | -21.8% |
Market Capitalization | 861.7M |
Book Value | $28.66 |
Earnings Per Share (EPS) | -0.21 |
Wall Street Target Price | 23.5 |
Profit Margin | -9.18% |
Operating Margin TTM | 10.85% |
Return On Assets TTM | 1.64% |
Return On Equity TTM | -0.78% |
Revenue TTM | 673.3M |
Revenue Per Share TTM | 14.45 |
Quarterly Revenue Growth YOY | -4.6% |
Gross Profit TTM | 450.0M |
EBITDA | 91.8M |
Diluted Eps TTM | -0.21 |
Quarterly Earnings Growth YOY | -0.37 |
EPS Estimate Current Year | 1.38 |
EPS Estimate Next Year | 1.85 |
EPS Estimate Current Quarter | 0.37 |
EPS Estimate Next Quarter | 0.26 |
What analysts predicted
Upside of 25.67%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 652.3M | ↑ 6.65% |
Net Income | 57.5M | ↓ 27.49% |
Net Profit Margin | 8.81% | ↓ 4.16% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 697.6M | ↑ 6.94% |
Net Income | -45.9M | ↓ 179.83% |
Net Profit Margin | -6.58% | ↓ 15.39% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 714.8M | ↑ 2.47% |
Net Income | -27.2M | ↓ 40.74% |
Net Profit Margin | -3.81% | ↑ 2.77% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 744.6M | ↑ 4.17% |
Net Income | 6.3M | ↓ 123.16% |
Net Profit Margin | 0.85% | ↑ 4.66% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 820.0M | ↑ 10.13% |
Net Income | 50.5M | ↑ 701.59% |
Net Profit Margin | 6.16% | ↑ 5.31% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 673.3M | ↓ 17.89% |
Net Income | -61.8M | ↓ 222.38% |
Net Profit Margin | -9.18% | ↓ 15.34% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 202.1M | ↓ 0.44% |
Net Income | 15.7M | ↑ 37.72% |
Net Profit Margin | 7.77% | ↑ 2.15% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 217.5M | ↑ 7.62% |
Net Income | 16.9M | ↑ 7.64% |
Net Profit Margin | 7.77% | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 191.7M | ↓ 11.86% |
Net Income | -500.0K | ↓ 102.96% |
Net Profit Margin | -0.26% | ↓ 8.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 169.4M | ↓ 11.63% |
Net Income | -68.1M | ↑ 13520.0% |
Net Profit Margin | -40.2% | ↓ 39.94% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 171.3M | ↑ 1.12% |
Net Income | -3.7M | ↓ 94.57% |
Net Profit Margin | -2.16% | ↑ 38.04% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 173.3M | ↑ 1.17% |
Net Income | 10.5M | ↓ 383.78% |
Net Profit Margin | 6.06% | ↑ 8.22% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↓ 16.51% |
Total Liabilities | 536.2M | ↓ 45.31% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↓ 1.84% |
Total Liabilities | 534.4M | ↓ 0.34% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↓ 7.05% |
Total Liabilities | 416.3M | ↓ 22.1% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↓ 4.67% |
Total Liabilities | 330.7M | ↓ 20.56% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 12.06% |
Total Liabilities | 495.7M | ↑ 49.89% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↓ 5.29% |
Total Liabilities | 456.1M | ↓ 7.99% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↑ 1.28% |
Total Liabilities | 511.7M | ↑ 2.09% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↑ 0.66% |
Total Liabilities | 495.7M | ↓ 3.13% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 2.91% |
Total Liabilities | 436.2M | ↓ 12.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 3.93% |
Total Liabilities | 431.9M | ↓ 0.99% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↑ 3.49% |
Total Liabilities | 502.8M | ↑ 16.42% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 1.88% |
Total Liabilities | 456.1M | ↓ 9.29% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -145.6M | ↓ 200.97% |
Investing Cash Flow | 639.5M | ↓ 1583.76% |
Financing Cash Flow | -324.4M | ↓ 14845.45% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -74.5M | ↓ 48.83% |
Investing Cash Flow | -108.1M | ↓ 116.9% |
Financing Cash Flow | 1.5M | ↓ 100.46% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.5M | ↓ 96.64% |
Investing Cash Flow | -24.2M | ↓ 77.61% |
Financing Cash Flow | -70.0M | ↓ 4766.67% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 87.3M | ↓ 3592.0% |
Investing Cash Flow | -21.0M | ↓ 13.22% |
Financing Cash Flow | -55.3M | ↓ 21.0% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 90.9M | ↑ 4.12% |
Investing Cash Flow | -135.4M | ↑ 544.76% |
Financing Cash Flow | 56.7M | ↓ 202.53% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 28.4M | ↑ 5.19% |
Investing Cash Flow | -4.7M | ↑ 14.63% |
Financing Cash Flow | -10.2M | ↓ 39.64% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 33.7M | ↑ 18.66% |
Investing Cash Flow | -4.9M | ↑ 4.26% |
Financing Cash Flow | -21.9M | ↑ 114.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.8M | ↓ 120.18% |
Investing Cash Flow | -4.0M | ↓ 18.37% |
Financing Cash Flow | -22.1M | ↑ 0.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.6M | ↓ 61.76% |
Investing Cash Flow | -6.5M | ↑ 62.5% |
Financing Cash Flow | -4.1M | ↓ 81.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 29.1M | ↓ 1219.23% |
Investing Cash Flow | -48.9M | ↑ 652.31% |
Financing Cash Flow | 46.7M | ↓ 1239.02% |
Sell
Neutral
Buy
Avanos Medical, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Avanos Medical, Inc. | -2.2% | 0.32% | -37.47% | -58.08% | -55.58% |
Stryker Corporation | -5.1% | 24.37% | 15.51% | 30.88% | 86.41% |
Boston Scientific Corp. | 1.07% | 34.02% | 31.68% | 66.24% | 93.56% |
Edwards Lifesciences Corp. | -6.04% | 25.15% | 3.43% | -1.49% | 47.65% |
Abbott Laboratories | -5.82% | 10.82% | 1.68% | -14.96% | 43.26% |
Medtronic Plc | -5.47% | 8.78% | -3.15% | -37.3% | -6.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Avanos Medical, Inc. | 52.7 | NA | NA | 1.38 | -0.01 | 0.02 | NA | 28.66 |
Stryker Corporation | 40.98 | 40.98 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 63.66 | 63.66 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 39.15 | 39.15 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 11.06 |
Abbott Laboratories | 33.4 | 33.4 | 5.99 | 4.59 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.16 | 25.16 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Avanos Medical, Inc. | Buy | $861.7M | -55.58% | 52.7 | -9.18% |
Stryker Corporation | Buy | $128.5B | 86.41% | 40.98 | 15.44% |
Boston Scientific Corp. | Buy | $100.1B | 93.56% | 63.66 | 11.18% |
Edwards Lifesciences Corp. | Buy | $54.2B | 47.65% | 39.15 | 23.36% |
Abbott Laboratories | Buy | $189.5B | 43.26% | 33.4 | 14.27% |
Medtronic Plc | Buy | $105.2B | -6.1% | 25.16 | 13.0% |
BlackRock Inc
Vanguard Group Inc
RGM Capital LLC
Dimensional Fund Advisors, Inc.
Westwood Holdings Group Inc
State Street Corporation
avanos is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter.headquartered in alpharetta, georgia, avanos is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery.avanos develops, manufactures and markets its recognized brands in more than 90 countries.
Organization | Avanos Medical, Inc. |
Employees | 3771 |
CEO | Mr. Joseph F. Woody |
Industry | Health Technology |